Table 1.
Additional Trop2-targeted ADCs in clinical development
| Name | Institute/Company | Phase/Clinical trial ID | Trial design/Patient population | Reference |
|---|---|---|---|---|
| BIO-106 | BiOneCure Therapeutics | Phase 1/2/ NCT05320588 | BIO-106 or BIO-106 + pembrolizumab in advanced cancers | Not applicable |
| BL-M02D1 | Biokin Pharmaceutical | Phase 1/2/ NCT05339685, NCT05385692, NCT05949619 | BL-M02D1 in locally advanced or metastatic TNBC or other solid tumors (NCT05339685); BL-M02D1 in locally advanced or metastatic gastroenteric tumors or other solid tumors (NCT05385692); BL-M02D1 in locally advanced or metastatic NSCLC or other solid tumors (NCT05949619) |
99 |
| 9MW2921 | Mabwell (Shanghai) Bioscience | Phase 1/2/ NCT05990452 | 9MW2921 in locally advanced or metastatic solid tumors refractory to all standard therapies | Not applicable |
| DB-1305 | Yinen Biopharmaceutical | Phase 1/2/ NCT05438329 | DB-1305 in advanced/unresectable, recurrent, or metastatic malignant solid tumors | 100 |
| IBI130 | Innovent Biologics | Phase 1/2/ NCT05923008 | IBI130 in unresectable, locally advanced, or metastatic solid tumors | Not applicable |
| HS-20105 | Hansoh Pharma | Phase 1/ NCT06144723 | HS-20105 in advanced solid tumors | Not applicable |
| BAT8008 | Bio-Thera Solutions | Phase 1/ NCT05620017 | BAT8008 in advanced solid tumors | 101 |
| FDA018 | Shanghai Fudan Zhangjiang Bio Pharmaceutical | Phase 1/ NCT05174637 | FDA018 in advanced solid tumors | Not applicable |
| FZ-AD004 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Phase 1/ NCT05914545 | FZ-AD004 in advanced/metastatic solid tumors | Not applicable |
| JS108 | Hangzhou DAC Biotechnology | Phase 1/ NCT04601285 | JS108 in advanced solid tumors | Not applicable |
| BAT8003 | Bio-Thera Solutions | Phase 1/ NCT03884517, terminated | BAT8003 in advanced epithelial cancer | 102 |
TNBC, triple-negative breast cancer; NSCLC, non-small cell lung cancer.